

## **R&D TAX INCENTIVE REFUND RECEIVED**

Neuroscientific Biopharmaceuticals Ltd (**ASX:NSB**) ("**NSB**", the "**Company**") is pleased to advise that it has received an R&D Tax Incentive refund of approximately \$1,134,710, from the Australian Federal Government, in relation to eligible R&D activities undertaken by the Company during the 2020/2021 financial year.

Following the receipt of this refund, the Company now has capital reserves of approximately \$6.34 million. The \$1,134,710 refund will be reinvested into the preclinical and clinical R&D programs currently being undertaken to support the commercialisation of NeuroScientific's lead drug candidate EmtinB.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Matthew Liddelow  
CEO and Managing Director  
ml@neuroscientific.com  
+ 61 8 6382 1805

Lucas Robinson  
Investor Relations  
Corporate Storytime  
[lucas@corporatestorytime.com](mailto:lucas@corporatestorytime.com)  
+ 61 408 228 889

### **About NeuroScientific Biopharmaceuticals Ltd**

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit [www.neuroscientific.com](http://www.neuroscientific.com)

### **About EmtinB™**

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.